|

TYRA-430 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • Tyra Biosciences, Inc1

Indications

  • Liver Disease1
  • Locally Advanced Unresectable Hepatocellular Carcinoma1
  • FGF19 Gene Overexpression1
  • FGF19 Gene Amplification1
  • FGFR4 Gene Fusions1

Los Angeles, California1 trial

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

USC Norris Comprehensive Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.